☰

Karen Liby, Ph.D. - Publications

Affiliations: 
2002 University of Cincinnati, Cincinnati, OH 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

66 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Occhiuto CJ, Moerland JA, Leal AS, Gallo KA, Liby KT. The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis. Molecules and Cells. 46: 176-186. PMID 36994476 DOI: 10.14348/molcells.2023.2191  0.304
2023 Reich LA, Leal AS, Ellsworth E, Liby KT. The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice. International Journal of Molecular Sciences. 24. PMID 36901727 DOI: 10.3390/ijms24054298  0.327
2023 Moerland JA, Leal AS, Lockwood B, Demireva EY, Xie H, Krieger-Burke T, Liby KT. The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner. Antioxidants (Basel, Switzerland). 12. PMID 36670978 DOI: 10.3390/antiox12010116  0.33
2022 Reich LA, Moerland JA, Leal AS, Zhang D, Carapellucci S, Lockwood B, Jurutka PW, Marshall PA, Wagner CE, Liby KT. The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports. 12: 293. PMID 34997154 DOI: 10.1038/s41598-021-04415-0  0.353
2021 Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers. 13. PMID 34638488 DOI: 10.3390/cancers13195004  0.382
2021 Zhang D, Hou Z, Aldrich KE, Lockwood L, Odom AL, Liby KT. A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy. Molecular Cancer Therapeutics. PMID 34158350 DOI: 10.1158/1535-7163.MCT-21-0210  0.379
2021 Zhang D, Singh B, Moerland J, Mitchell O, Lockwood L, Carapellucci S, Sridhar S, Liby KT. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. Scientific Reports. 11: 1234. PMID 33441637 DOI: 10.1038/s41598-020-79663-7  0.315
2020 Leal AS, Liu P, Krieger-Burke T, Ruggeri B, Liby KT. The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer. Cancers. 13. PMID 33396954 DOI: 10.3390/cancers13010096  0.347
2020 Moerland JA, Zhang D, Reich LA, Carapellucci S, Lockwood B, Leal AS, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports. 10: 22244. PMID 33335263 DOI: 10.1038/s41598-020-79260-8  0.371
2020 Ball MS, Bhandari R, Torres GM, Martyanov V, ElTanbouly MA, Archambault K, Whitfield ML, Liby KT, Pioli PA. CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. Scientific Reports. 10: 6560. PMID 32300202 DOI: 10.1038/s41598-020-63482-x  0.309
2019 Leal AS, Zydeck K, Carapellucci S, Reich LA, Zhang D, Moerland JA, Sporn MB, Liby KT. Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. Npj Breast Cancer. 5: 39. PMID 31700995 DOI: 10.1038/s41523-019-0135-5  0.341
2019 Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, Liby KT. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics. 9: 6224-6238. PMID 31534547 DOI: 10.7150/Thno.36281  0.343
2019 Leal AS, Misek SA, Lisabeth EM, Neubig RR, Liby KT. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras; Pdx1-Cre (KC) mice. Scientific Reports. 9: 7072. PMID 31068602 DOI: 10.1038/s41598-019-43430-0  0.302
2019 Zhang D, Livingston C, Dexheimer T, Ellsworth E, Odom A, Liby K. Abstract 1: A small molecule inhibits Nrf2 expression and activity in cancer cells Cancer Research. 79: 1-1. DOI: 10.1158/1538-7445.Am2019-1  0.451
2019 Zhang D, Aldrich K, Dexheimer T, Ellsworth E, Odom A, Liby K. Abstract C063: A novel Nrf2 inhibitor suppresses proliferation and enhances the sensitivity of cancer cells to chemotherapy Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C063  0.477
2018 Kolsi LE, Leal AS, Yli-Kauhaluoma J, Liby KT, Moreira VM. Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1. Scientific Reports. 8: 15923. PMID 30374056 DOI: 10.1038/S41598-018-34131-1  0.324
2018 Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT. Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Antioxidants & Redox Signaling. PMID 29634345 DOI: 10.1089/Ars.2017.7201  0.342
2018 Zhang D, Rennhack J, Andrechek E, Rockwell C, Liby K. Abstract 4051: Different immune signatures in advanced lung tumors of Nrf2 wildtype vs. knockout mice Cancer Research. 78: 4051-4051. DOI: 10.1158/1538-7445.Am2018-4051  0.403
2017 Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT. Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762. Cancer Prevention Research (Philadelphia, Pa.). PMID 29246957 DOI: 10.1158/1940-6207.Capr-17-0264  0.409
2017 Chakraborty D, Benham V, Jdanov V, Bullard B, Leal AS, Liby KT, Bernard JJ. A BET bromodomain inhibitor suppresses adiposity-associated malignant transformation. Cancer Prevention Research (Philadelphia, Pa.). PMID 29246955 DOI: 10.1158/1940-6207.CAPR-17-0262  0.33
2017 Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, Sridhar S. Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics. 7: 4340-4349. PMID 29158830 DOI: 10.7150/Thno.18563  0.306
2017 Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters. PMID 28254412 DOI: 10.1016/J.Canlet.2017.02.021  0.324
2017 Belz J, Ojo NC, Baldwin P, Kumar R, Ven Avd, Liby K, Cormack R, Makrigiorgos M, Sridhar S. Abstract B30: Sustained release of PARP inhibitor Talazoparib and chemotherapeutic Docetaxel from modified brachytherapy spacers for treatment of breast and prostate cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-B30  0.435
2017 Baldwin P, Ohman A, Belz J, Thong J, Ojo NC, Liby K, Dinulescu D, Sridhar S. Abstract B29: Nanoformulations and sustained delivery systems for the PARP inhibitors Olaparib and Talazoparib Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-B29  0.43
2017 Baldwin P, Kumar R, Favours E, Liby K, Kurmasheva R, Kozono D, Sridhar S. Abstract 3100: Nanoformulated Talazoparib and Olaparib for enhanced delivery Cancer Research. 77: 3100-3100. DOI: 10.1158/1538-7445.Am2017-3100  0.383
2016 Liby KT, Sporn MB. Rexinoids for prevention and treatment of cancer: opportunities and challenges. Current Topics in Medicinal Chemistry. PMID 27320330 DOI: 10.2174/1568026616666160617090702  0.337
2016 Ball MS, Shipman EP, Kim H, Liby KT, Pioli PA. CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. Plos One. 11: e0149600. PMID 26918785 DOI: 10.1371/Journal.Pone.0149600  0.322
2016 Belz J, Ojo NC, Baldwin P, Kumar R, Ven Avd, Liby K, Cormack R, Makrigiorgos M, Sridhar S. Abstract 3900: Sustained release of PARP inhibitor Talazoparib and chemotherapeutics from biodegradable implants for treatment of breast and prostate cancer Cancer Research. 76: 3900-3900. DOI: 10.1158/1538-7445.Am2016-3900  0.409
2015 Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT. The rexinoids LG100268 and LG101506 inhibit inflammation and suppress lung carcinogenesis in A/J mice. Cancer Prevention Research (Philadelphia, Pa.). PMID 26554632 DOI: 10.1158/1940-6207.Capr-15-0325  0.341
2015 To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. PMID 25939751 DOI: 10.1093/Carcin/Bgv061  0.373
2015 Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle (Georgetown, Tex.). 14: 648-55. PMID 25590338 DOI: 10.4161/15384101.2014.994966  0.308
2015 Cao M, Onyango E, Williams C, Royce D, Gribble G, Sporn M, Liby K. Abstract 5559: Novel synthetic pyridyl analogues of CDDO-Im with improved stability and their potential use in cancer prevention Cancer Research. 75: 5559-5559. DOI: 10.1158/1538-7445.Am2015-5559  0.456
2015 Belz J, Liby K, Baldwin P, Kumar R, Ven ALvd, Cormack R, Makrigiorgos M, Sridhar S. Abstract B42: Sustained release of PARP inhibitor Talazoparib from bioedgradable implant for treatment of BRCA1-mutated breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B42  0.447
2014 So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. Plos One. 9: e107616. PMID 25229616 DOI: 10.1371/Journal.Pone.0107616  0.359
2014 Liby KT. Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer. Dose-Response : a Publication of International Hormesis Society. 12: 136-51. PMID 24659938 DOI: 10.2203/dose-response.13-018.Liby  0.358
2013 So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, Maehr H, Uskokovic M, Liby KT, Sporn MB, Suh N. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prevention Research (Philadelphia, Pa.). 6: 959-70. PMID 23856074 DOI: 10.1158/1940-6207.Capr-13-0087  0.403
2013 Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J. ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Research. 73: 1020-30. PMID 23243027 DOI: 10.1158/0008-5472.Can-12-2862  0.463
2013 Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 34: 199-210. PMID 23042302 DOI: 10.1093/Carcin/Bgs319  0.348
2013 So JY, Smolarek AK, Maehr H, Uskokovic M, Liby K, Sporn MB, Suh N. Abstract 180: Inhibition of tumorigenesis by a novel Gemini vitamin D analog BXL0124 and a synthetic triterpenoid CDDO-Im in MMTV-HER2/neu transgenic mice. Cancer Research. 73: 180-180. DOI: 10.1158/1538-7445.Am2013-180  0.476
2012 Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prevention Research (Philadelphia, Pa.). 5: 726-34. PMID 22401982 DOI: 10.1158/1940-6207.Capr-11-0404  0.398
2012 Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prevention Research (Philadelphia, Pa.). 5: 89-97. PMID 21933912 DOI: 10.1158/1940-6207.Capr-11-0359  0.348
2012 Liby K, Royce D, Williams C, Risingsong R, Tran K. Abstract B22: The evaluation of the synthetic triterpenoid CDDO-ethyl amide and the histone deacetylase inhibitor vorinostat for prevention of pancreatic cancer . Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-B22  0.441
2011 Kim EH, Deng CX, Sporn MB, Liby KT. CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prevention Research (Philadelphia, Pa.). 4: 425-34. PMID 21372041 DOI: 10.1158/1940-6207.Capr-10-0153  0.322
2011 Tran KM, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. Abstract A103: The synthetic triterpenoid CDDO-methyl ester targets tumor-associated macrophages to delay carcinogenesis in the PyMT model of estrogen receptor negative breast cancer Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A103  0.473
2011 Tran KM, Sporn MB, Liby K. Abstract 820: The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, and the histone deacetylase inhibitor vorinostat delay carcinogenesis in a transgenic model of estrogen receptor-negative breast cancer Cancer Research. 71: 820-820. DOI: 10.1158/1538-7445.Am2011-820  0.447
2010 Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 1427-34. PMID 20959520 DOI: 10.1158/1940-6207.Capr-10-0197  0.316
2010 Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1812-23. PMID 20215551 DOI: 10.1158/1078-0432.Ccr-09-3272  0.319
2009 Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prevention Research (Philadelphia, Pa.). 2: 1050-8. PMID 19952361 DOI: 10.1158/1940-6207.Capr-09-0085  0.41
2008 Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, et al. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin Cancer Research. 68: 6727-6733. PMID 18701497 DOI: 10.1158/0008-5472.Can-08-1123  0.36
2008 Liby K, Risingsong R, Royce DB, R. Williams C, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB. Prevention and treatment of experimental estrogen receptor- negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268 Clinical Cancer Research. 14: 4556-4563. PMID 18628471 DOI: 10.1158/1078-0432.Ccr-08-0040  0.42
2008 Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis Molecular Cancer Therapeutics. 7: 1251-1257. PMID 18483313 DOI: 10.1158/1535-7163.Mct-08-0023  0.397
2008 Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS. Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biology & Therapy. 7: 709-17. PMID 18277094 DOI: 10.4161/Cbt.7.5.5713  0.406
2007 Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6237-43. PMID 17947492 DOI: 10.1158/1078-0432.Ccr-07-1342  0.4
2007 Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities Molecular Cancer Therapeutics. 6: 2113-2119. PMID 17620440 DOI: 10.1158/1535-7163.Mct-07-0180  0.415
2007 Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice Cancer Research. 67: 2414-2419. PMID 17363558 DOI: 10.1158/0008-5472.Can-06-4534  0.414
2007 Hock TD, Liby K, Wright MM, McConnell S, Schorpp-Kistner M, Ryan TM, Agarwal A. JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells. The Journal of Biological Chemistry. 282: 6875-86. PMID 17204476 DOI: 10.1074/Jbc.M608456200  0.328
2006 Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5902-9. PMID 17020999 DOI: 10.1158/1078-0432.Ccr-06-1119  0.413
2006 Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4288-93. PMID 16857804 DOI: 10.1158/1078-0432.Ccr-06-0215  0.401
2005 Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Research. 65: 4789-98. PMID 15930299 DOI: 10.1158/0008-5472.Can-04-4539  0.338
2004 Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Research. 64: 3566-71. PMID 15150113 DOI: 10.1158/0008-5472.Can-04-0234  0.454
2003 Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Research and Treatment. 79: 241-52. PMID 12825859 DOI: 10.1023/A:1023956223037  0.629
2003 Liby K, Neltner B, Mohamet L, Burd C, Ben-Jonathan N. Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. Cancer Biology & Therapy. 2: 48-52. PMID 12673115 DOI: 10.4161/Cbt.179  0.618
2002 Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism: Tem. 13: 245-50. PMID 12128285 DOI: 10.1016/S1043-2760(02)00603-3  0.594
2001 Liby K, Wu H, Ouyang B, Wu S, Chen J, Dai W. Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase Mitochondrial Dna. 11: 527-533. PMID 11696980 DOI: 10.3109/10425170109041337  0.344
1999 Khurana S, Liby K, Buckley AR, Ben-Jonathan N. Proteolysis of Human Prolactin: Resistance to Cathepsin D and Formation of a Nonangiostatic, C-Terminal 16K Fragment by Thrombin1. Endocrinology. 140: 4127-4132. PMID 28200812 DOI: 10.1210/endo.140.9.6955  0.476
1999 Khurana S, Liby K, Buckley AR, Ben-Jonathan N. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology. 140: 4127-32. PMID 10465285 DOI: 10.1210/Endo.140.9.6955  0.545
Show low-probability matches.